Quadrant Capital Group LLC Boosts Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Quadrant Capital Group LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,287 shares of the company’s stock after purchasing an additional 93 shares during the period. Quadrant Capital Group LLC’s holdings in Medpace were worth $760,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of MEDP. Proficio Capital Partners LLC increased its position in shares of Medpace by 34,497.4% during the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after buying an additional 241,827 shares during the period. Raymond James Financial Inc. bought a new position in shares of Medpace in the 4th quarter worth approximately $78,144,000. Norges Bank purchased a new position in shares of Medpace in the 4th quarter valued at approximately $69,859,000. GW&K Investment Management LLC grew its stake in Medpace by 93.9% in the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after purchasing an additional 133,379 shares during the period. Finally, Wellington Management Group LLP raised its holdings in Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on MEDP shares. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research report on Monday, March 24th. Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Finally, Leerink Partners assumed coverage on Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective for the company. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus price target of $376.30.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $287.11 on Monday. Medpace Holdings, Inc. has a 1 year low of $282.42 and a 1 year high of $459.77. The stock’s fifty day moving average price is $331.56 and its 200-day moving average price is $337.32. The company has a market cap of $8.75 billion, a P/E ratio of 22.73, a PEG ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.